Sanofi is expected to report Q1 2026 revenue of $11.99 billion and EPS of $1.04, with the stock currently trading near $48.06 compared to an average analyst price target of $57.00.
Investors are primarily focused on the sales trajectory of the blockbuster immunology drug Dupixent, particularly its performance following recent label expansions into COPD and chronic spontaneous urticaria.
Market sentiment is bolstered by the company's recent strategic pivot, including the planned €1.0 billion share buyback for 2026 and the integration of proceeds from the €10.4 billion Opella consumer health divestment into its R&D pipeline.
Recent regulatory milestones, such as the EU approval of Rezurock and positive Phase 2 data for lunsekimig in asthma, provide further evidence of Sanofi's efforts to diversify its growth drivers beyond its core franchises.